DOI: 10.1055/s-00000030

Der Klinikarzt


Loibl S, Untch M, Burchardi N. et al.
A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

J Clin Oncol 2017;
35 (15_suppl) 3062-3062

Download Bibliographical Data

Search in: